Clinical trial · Observational
Evaluation of Neoadjuvant Therapy Efficacy and Postoperative Pathological Indicators in Esophageal Cancer Using CT and Multimodal MRI
NCT06833775CI-TRIAL-00086232not yet recruitingClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study aims to predict the efficacy of different types of neoadjuvant therapy and related postoperative pathological indicators in patients with esophageal cancer based on imaging parameters from CT and multimodal MRI, as well as clinical indicators collected before and after neoadjuvant treatment.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Esophageal Cancer | Malignant Esophageal Neoplasm | CURATED_EXACT | 0.92 |
| Neoadjuvant Therapy | — | UNRESOLVED | — |
Interventions
Interventions (0)
Data not yet available
No intervention recorded.
Design
Arms and outcomes
Arms (2)
- label
- the group of patients who achieved pathological complete response (pCR) following neoadjuvant
- label
- the group of patients who did not achieve pCR following neoadjuvant therapy and surgery for esophage
Primary outcomes (1)
- measure
- CT and multimodal MRI in prediction of neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer
- timeFrame
- March 2025 - January 2030
- description
- To evaluate the effectiveness of CT and multimodal MRI in determining the neoadjuvant therapy efficacy and postoperative pathological indicators in esophageal cancer.
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: 1. Consecutive patients with histopathological diagnosis of esophageal cancer. 2. Patients underwent neoadjuvant therapy before radical surgery for esophageal cancer: neoadjuvant chemotherapy, neoadjuvant chemoradiotherapy, neoadjuvant chemotherapy plus immunotherapy, neoadjuvant chemoradiotherapy plus immunotherapy. 3. All patients underwent CT and multimodal MRI examinations before and after neoadjuvant therapy. 4. The preoperative clinical data and postoperative pathological data are complete. Exclusion Criteria: 1. Patients with other primary malignant tumors or previous anti-tumor treatment. 2. CT and MRI images with poor quality.
References
Publications (0)
Data not yet available
No reference posted for this study.